BioCryst Pharmaceuticals, Inc.

Good morning and welcome to the Biochrist Pharmaceuticals third quarter 2023 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing star then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To redraw your question, please press star, then two. Please note, this event is being recorded. I would like now to turn the conference over to John Bluth at Biochrist. Please go ahead.

Thank you, Maria. Good morning, and welcome to Biochrist's third quarter 2023 corporate update and financial results conference call. Today's press release and accompanying slides are available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, and Chief Data and Insights Officer Jinky Roselli. Following our remarks, we'll answer your questions. As a reminder, tomorrow at 1 p.m. Eastern time, we'll be hosting an R&D day where we plan to describe our drug discovery process and introduce additional therapies from our pipeline. So today, we'll focus on Orlodeo, and tomorrow, we'll take a deep dive and answer your question on our pipeline programs. Before we begin, please note that today's conference call will contain certain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. In addition, today's conference call includes non-GAAP pro forma financial measures. For reconciliation of these non-GAAP measures against the most directly comparable GAAP financial measure, please refer to the earnings press release posted in the press release section of our investor relations website at biocrist.com. Now I'd like to turn the call over to John Stonehouse.

Thanks, John. Third quarter Orladeo revenue of $85.7 million was another strong quarter of performance. and gives us a high degree of confidence, we will achieve our goal of no less than $320 million for the year and remain on track for the $1 billion at peak. This growing revenue, along with discipline around our capital allocation, put us in a very strong financial position heading into the end of the year. Since we have more time today to discuss Orlodeo, we'll go deeper into what we see in the market and how we see the market changing over time. As John mentioned, you will also hear from another member of the team today. Jinky has been with Biochris for over eight years. Jinky's title is Chief Data and Insights Officer, but to simply explain her role, Jinky gathers data and insights across the company and in the marketplace to help us understand the truth of what's really going on, not to look for data supporting what we hope to be true. This is a very important distinction. She will share the data and insights she and her team have gathered around the HAE market and Orla Deo, both today and what we see that will impact the future. We hope this will help you understand what we see and why we remain confident in our current growth trajectory and the path to peak revenue of $1 billion. Now I'll turn it over to Charlie to talk about the quarter's performance.